Takeda to Acquire ARIAD Pharmaceuticals

By | February 5, 2017

Takeda Pharmaceuticals has announced it will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, for a total value of approximately $5.2 billion. The transaction is expected to close by the end of February 2017. The acquisition of Cambridge-based ARIAD adds new investigational oncology products to Takeda’s pipeline, including Brigatinib for specific forms of non-small cell lung cancer (NSCLC) and Iclusig, for specific forms of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). (Source: takeda.com and ariad.com)